Cointime

Splisense

company

About

Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations.

  • Jerusalem,Yerushalayim,Israel
  • 1 - 10

Highlights

Total Funding Amount
$28.50M
Funding Rounds
2
Investors
5
Employee Profiles
3

Details

Last Funding Type
Series B
Last Funding Money Raised
$28.50M
Industries
Biotechnology,Life Science,Pharmaceutical
Founded date
Jan 1, 2016
Number Of Employee
1 - 10
Operating Status
Active
Legal Name
Splisense Ltd.

Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTR transcripts according to the specific mutation carried.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$28.50M
Splisense has raised a total of $28.50M in funding over 2 rounds. Their latest funding was raised on May 13, 2021 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 13, 2021 Series B $28.50M 5 Cystic Fibrosis Foundation — Detail
Jan 1, 2016 Seed — 1 Integra Holdings — Detail

Investors

Number of Lead Investors
Number of Investors
2
5
Splisense is funded by 5 investors. Cystic Fibrosis Foundation and Biotel are the most recent investors.
Investor Name Lead Investor Funding Round
Cystic Fibrosis Foundation Yes Series B
Biotel — Series B
Integra Holdings — Series B
Israel Biotech Fund — Series B
OrbiMed — Series B

Employee Profiles

Number of Employee Profiles
3
Splisense has 3 current employee profiles, including Executive Dr. Gili Hart
Dr. Gili Hart
Executive
Dr. Nissim Darvish
Board member
Cointime
İçerikler
Şirket.